指南与共识乳腺癌

中国晚期乳腺癌规范诊疗指南(2024版)

[Guidelines for diagnosis and treatment of advanced breast cancer in China (2024 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2024-01-01

2022年中国女性乳腺癌新发约35.7万例、死亡约7.5万例,约5%~10%新发患者确诊时即有远处转移,早期患者中约20%~30%最终进展为晚期乳腺癌。中国专家基于2022版指南及最新循证证据更新形成2024版指南,纳入分子病理检测新理念、精准医学新进展及新型治疗药物不良反应等内容,强调多学科协作和患者报告结局,为临床医师提供晚期乳腺癌诊疗推荐。

要点

  • 2022年中国女性乳腺癌新发约35.7万例,死亡约7.5万例。
  • 约5%~10%新发患者确诊时即有远处转移。
  • 早期患者中约20%~30%最终发展为晚期乳腺癌。

核心结论

  • 晚期乳腺癌虽难以治愈,但可通过应用新型治疗药物、优化治疗模式等缓解临床症状、改善生活质量、延长生存时间,以期达到长期带瘤生存。

研究设计与样本

  • 国家肿瘤质控中心乳腺癌专家委员会、中国抗癌协会乳腺癌专业委员会和中国抗癌协会肿瘤药物临床研究专业委员会专家基于国内外晚期乳腺癌临床研究进展及专家意见,在《中国晚期乳腺癌规范诊疗指南(2022版)》基础上更新形成2024版指南。

主要发现

  • 2022年中国女性乳腺癌新发病例数约为35.7万例,死亡病例数约为7.5万例。
  • 每年新发乳腺癌患者中约5%~10%在确诊时即有远处转移。
  • 早期患者中约20%~30%最终发展为晚期乳腺癌。

关键数值与推荐

  • 2024版指南纳入晚期乳腺癌领域高质量循证医学新证据、分子病理检测新理念、综合治疗新方案、精准医学新进展、新型治疗药物不良反应。
  • 2024版指南强调多学科协作并关注患者报告结局。
  • 2024版指南旨在为中国临床医师提供晚期乳腺癌诊断与治疗推荐。

临床怎么用

  • 2024版指南供临床医师参考,用于中国晚期乳腺癌的诊断与治疗决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignant tumor among women all over the world. In 2022, there were about 357,161 new cases and 74,986 deaths of breast cancer in Chinese female. Of the new cases of breast cancer each year, about 5% to 10% of patients have distant metastasis at the time of diagnosis. Of the early-stage patients, about 20%~30% developed into advanced breast cancer eventually. Although advanced breast cancer is difficult to cure at present, we can alleviate the clinical symptoms of patients, improve their quality of life and further prolong their survival time by applying new therapeutic drugs and optimizing treatment models, to achieve the purpose of long-term survival with tumor. To better guide clinical practice, the Chinese expert group, based on the latest research progress in breast cancer, has analyzed, discussed, and updated the relevant research data on the basis of "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2022 edition)" to form the "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2024 edition)" . The updated guideline incorporates the new evidence of high-quality evidence-based medicine, new concepts in molecular pathological detection, new treatment strategies, new progress in precision medicine, and adverse events of new therapeutic drugs. At the same time, the updated guideline emphasizes multidisciplinary collaboration and pays attention to patient-reported outcomes. The "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2024 edition)" aims to provide clinicians with recommendations for the diagnosis and treatment of advanced breast cancer in China, thereby improving patient outcomes and quality of life. 乳腺癌是全球女性最常见的恶性肿瘤,2022年中国乳腺癌新发病例数约为35.7万例,死亡病例数约为7.5万例,严重危害女性健康。在每年新发乳腺癌患者中,约5%~10%的患者在确诊时即有远处转移。早期患者中约20%~30%最终发展为晚期乳腺癌。晚期乳腺癌虽难以治愈,但可通过应用新型治疗药物、优化治疗模式等方法来缓解临床症状,改善生活质量,进一步延长生存时间,以期达到长期带瘤生存的目的。为了更好地指导临床实践,国家肿瘤质控中心乳腺癌专家委员会、中国抗癌协会乳腺癌专业委员会和中国抗癌协会肿瘤药物临床研究专业委员会专家基于国内外晚期乳腺癌临床研究进展及专家意见,经过详尽讨论和总结,在《中国晚期乳腺癌规范诊疗指南(2022版)》基础上进行更新。2024版指南纳入晚期乳腺癌领域高质量循证医学新证据、分子病理检测新理念、综合治疗新方案、精准医学新进展、新型治疗药物不良反应等,同时强调多学科协作、关注患者报告结局,最终形成《中国晚期乳腺癌规范诊疗指南(2024版)》,以供临床医师参考。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Guidelines for diagnosis and treatment of advanced breast cancer in China (2024 edition)]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 39632259. doi:10.3760/cma.j.cn112152-20241009-00435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。